Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million
Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline developments, and government initiatives shaping the genetic therapeutics landscape.
Ottawa, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The market for gene therapy and CRISPR-based therapeutics continues to grow rapidly, driven by breakthroughs in AAV-based therapies, ex vivo gene editing, and regenerative medicine. While some companies have started generating meaningful product revenue, others remain in clinical stages, funded through collaborations, cash reserves, and strategic acquisitions.
Invest in Our Premium Strategic Solution: https://www.precedenceresearch.com/request-consultation/42
Key Company Insights
The table below summarizes financial and operational highlights from major players in the gene therapy and CRISPR therapeutics sector:
| Company | Country | Latest Revenue / Sales (USD) | Genetic Therapeutics Segment Data | Notes / Highlights |
| CRISPR Therapeutics AG | Switzerland & USA | Not profitable yet | FY 2023 revenue: ~$20M (product/collaboration) | Significant collaborations; ongoing development programs |
| Intellia Therapeutics, Inc. | USA | Not meaningful in product sales | Cash position ~$1.0B (Dec 2023) | Focus on in vivo/ex vivo CRISPR platforms; no marketed products |
| Sarepta Therapeutics, Inc. | USA | Q1 2025: $611.5M | Net product revenue ~$611.5M, mainly Elevidys | Elevidys: AAV-based therapy for Duchenne muscular dystrophy |
| Spark Therapeutics, Inc. (Roche subsidiary) | USA | $64M (2018) | Developer of Luxturna | Focused on inherited retinal disease gene therapy |
| BioMarin Pharmaceutical Inc. | USA | $2.419B (2023) | Roctavian sales ~$3.5M | Rare disease gene therapy; expanded via Amicus acquisition |
| Novartis AG (Zolgensma) | Switzerland | ~$53B group revenue | Zolgensma sales ~$1.2B | AAV therapy for spinal muscular atrophy |
| Vertex Pharmaceuticals | USA | ~$9.85B (2023 total) | Casgevy gene-editing therapy sales ~$14.2M | Partnership with CRISPR; small contribution to overall revenue |
| MeiraGTx Holdings | UK / USA | Not disclosed | $475M+ deal with Eli Lilly | Ophthalmology AAV-based therapy (AIPL1) |
| Verve Therapeutics | USA | Not public | Acquired by Eli Lilly up to $1.3B | Gene editing for PCSK9 cardiovascular therapies |
| Eli Lilly Ltd | USA | ~$30B+ overall | Genetic therapy acquisitions | Expanding gene editing via deals & pipelines |
| Orchard Therapeutics | UK | Not widely published | Focused on ex vivo gene-corrective therapies | Partnerships with Kyowa Kirin for rare diseases |
| Sangamo Therapeutics | USA | No recent products | Clinical stage gene editing & in vivo AAV programs | Development pipeline ongoing |
| Gilead Sciences | USA | ~$27B+ (2024) | Lentiviral CAR-T, gene editing programs | Involved via Kite & other CGT programs |
| Amgen, Inc. | USA | ~$27B+ (2024) | Gene editing/cell therapy R&D | Broad pharma involvement |
| Biogen Inc. | USA | $9.835B (2023) | Gene editing workflows; nusinersen separate | Focus on genomics & rare diseases pipeline |
Request Research Report Built Around Your Goals: sales@precedenceresearch.com
Government & Public Sector Initiatives
Governmental and regulatory bodies worldwide are actively supporting gene therapy research and commercialization. While direct spending is often embedded in broader health budgets, key initiatives include:
| Region | Agency / Program | Funding / Initiative | Details |
| USA | NIH & FDA | Ongoing approvals & funding directives | Multiple gene therapy products approved; Zolgensma generates ~$1.2B revenue |
| European Union | EMA | Regulatory approvals | EMA approves AAV gene therapies; budget not publicly disclosed |
| UK | NHS | Clinical reimbursements | Royal NHS funds approved therapies for SMA & rare diseases |
| Japan | MHLW | Regenerative Medicine Act | Conditional approvals for gene therapies enabled |
| China | National Medical Products Administration | Genomic medicine approvals | Supports in vivo gene therapy trials; pipeline expansion |
Market Trends & Insights
- Revenue Generation: Companies such as Sarepta, Novartis, and BioMarin have begun generating meaningful revenue from marketed gene therapies, with Elevidys and Zolgensma leading commercial adoption.
- Clinical Stage Growth: Smaller biotech players like CRISPR Therapeutics, Intellia, and Sangamo remain primarily in clinical development but hold significant potential due to partnerships and innovative platforms.
- Government Support: Regulatory pathways in the US, EU, Japan, UK, and China accelerate gene therapy commercialization, though direct numeric funding is often embedded in broader budgets.
- Strategic M&A: Acquisitions by Eli Lilly and Roche demonstrate the growing strategic interest in gene editing and gene therapy pipelines.
How Precedence Research Can Help
At Precedence Research, we provide in-depth, actionable insights that go beyond surface-level data:
- Detailed revenue, pricing, and product forecasts for gene therapy and CRISPR therapeutics.
- Segment-specific financial and operational data, including collaborations, partnerships, and pipeline value.
- Government and regulatory landscape mapping with funding allocations, approvals, and incentives.
- Market modeling with CAGR projections, historical trends, and scenario analysis.
- Customized strategic reports tailored to your business needs, supporting M&A, investment, or R&D decisions.
Contact Us:
Email: sales@precedenceresearch.com
USA: +1 8044 419344 | APAC: +61 4859 81310 / +91 87933 22019 | Europe: +44 7383 092 044
Precedence Research – Turning Data Noise Into Strategic Clarity.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
